Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD, Leeds Teaching Hospital NHS Trust, Leeds, UK, discusses patient preferences for the treatment of their paroxysmal nocturnal hemoglobinuria (PNH). Dr Hill specifically mentions the results of a patient survey of ravulizumab (alxn1210) and eculizumab. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
Негізгі бет PNH treatment: ravulizumab vs. eculizumab
No video
Пікірлер